AbbVie trumpets Skyrizi's resounding win against J&J's Stelara in Crohn's disease

AbbVie already shared last month that its Skyrizi had trounced Johnson & Johnson’s rival biologic drug Stelara in Crohn’s disease. Now, detailed trial results show just how decisive Skyrizi’s win is.